XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(Q1)Dec 31, 2024 | (FY)Sep 30, 2024 | (Q4)Sep 30, 2024 | (Q3)Jun 30, 2024 | (Q2)Mar 31, 2024 | (Q1)Dec 31, 2023 | (FY)Sep 30, 2023 | (Q4)Sep 30, 2023 | (Q3)Jun 30, 2023 | (Q2)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 324.32%249M | -15.52%1.57B | -2.83%996M | 25.58%1.02B | -207.64%-338M | 62.50%-111M | 50.04%1.86B | 140.61%1.03B | 66.94%813M | 561.76%314M |
Net income from continuing operations | 6.18%361M | -10.75%1.41B | 46.51%189M | -6.24%1.05B | -197.70%-170M | 117.95%340M | 22.18%1.58B | -66.05%129M | 153.27%1.12B | 234.62%174M |
Operating gains losses | 0.00%-16M | -98.18%1M | -72.38%29M | 1,075.00%94M | -2,750.00%-106M | 74.19%-16M | 125.11%55M | 151.98%105M | -42.86%8M | -94.20%4M |
Depreciation and amortization | -7.21%193M | 9.53%816M | 4.03%129M | 3.77%220M | 25.73%259M | 2.46%208M | 3.91%745M | 47.62%124M | 5.47%212M | -0.96%206M |
Deferred tax | 32.50%-54M | 33.06%-403M | 95.78%-14M | 110.78%11M | -321.05%-320M | 13.04%-80M | -216.84%-602M | -750.98%-332M | 29.17%-102M | -16.92%-76M |
Other non cash items | 223.08%16M | -55.74%293M | 2.91%106M | 21.05%-15M | -32.81%215M | -105.04%-13M | 55.04%662M | -18.90%103M | -124.05%-19M | 10.34%320M |
Change In working capital | 51.81%-279M | 5.06%-657M | -39.39%534M | 15.95%-369M | 29.57%-243M | 26.62%-579M | 22.25%-692M | 2,769.70%881M | -242.97%-439M | 46.92%-345M |
-Change in receivables | 610.00%284M | -107.34%-537M | -44.61%226M | 66.12%-104M | -156.99%-699M | 145.45%40M | 36.67%-259M | 78.95%408M | 7.25%-307M | -17.75%-272M |
-Change in inventory | 85.85%-15M | 70.69%-17M | -39.08%198M | -88.18%13M | 15.86%-122M | 69.54%-106M | 89.24%-58M | 46.40%325M | 177.46%110M | 40.33%-145M |
-Change in payables and accrued expense | -24.67%-379M | 285.71%455M | -62.89%36M | 136.44%90M | 210.29%633M | -1.67%-304M | -158.89%-245M | 124.07%97M | -162.06%-247M | 3,980.00%204M |
-Change in other current assets | 12.31%-171M | -157.75%-482M | 162.96%71M | -675.56%-349M | 91.09%-9M | -186.76%-195M | 46.42%-187M | 136.99%27M | 35.71%-45M | 29.37%-101M |
-Change in other working capital | 114.29%2M | -233.33%-76M | -87.50%3M | -138.00%-19M | -48.39%-46M | -200.00%-14M | 733.33%57M | 442.86%24M | 194.12%50M | 18.42%-31M |
Cash from discontinued investing activities | 98.52%-2M | 45.21%530M | -135M | -51.53%365M | ||||||
Operating cash flow | 200.41%247M | -5.54%2.1B | 9.78%1.53B | 25.58%1.02B | -164.65%-203M | 16.89%-246M | 11.61%2.22B | 17.50%1.39B | 66.94%813M | 561.76%314M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -64.06%-105M | 83.17%-184M | 124.37%126M | 62.21%-99M | -17.60%-147M | 66.14%-64M | -85.88%-1.09B | -517M | -2.34%-262M | -9.65%-125M |
Capital expenditure reported | -41.46%-116M | -10.76%-494M | -112.50%-170M | 10.81%-99M | -18.18%-143M | 38.81%-82M | 8.42%-446M | -40.35%-80M | 34.71%-111M | 3.20%-121M |
Net PPE purchase and sale | ---- | -96.67%1M | ---- | ---- | ---- | ---- | -76.38%30M | ---- | ---- | ---- |
Net business purchase and sale | ---- | 149.00%342M | 177.85%341M | --0 | ---- | ---- | -159.48%-698M | -1,227.27%-438M | -33.59%-171M | 37.50%-10M |
Net other investing changes | -38.89%11M | -257.14%-33M | -58.62%-46M | --0 | -183.33%-5M | -25.00%18M | -48.78%21M | -3,000.00%-29M | -48.72%20M | --6M |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | -55.41%-115M | 81.33%-221M | 114.64%89M | 62.21%-99M | -9.60%-137M | 60.85%-74M | -70.85%-1.18B | -479.05%-608M | -2.34%-262M | -9.65%-125M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -83.74%201M | 5.39%-1.95B | -71.52%-1.63B | 27.24%-999M | -320.95%-559M | 13,633.33%1.24B | -421.27%-2.06B | -123.58%-948M | -230.84%-1.37B | -68.41%253M |
Net issuance payments of debt | -48.83%787M | 188.62%405M | -32.35%-1.12B | 62.41%-256M | -62.91%240M | 265.32%1.54B | -123.25%-457M | -214.93%-844M | -489.14%-681M | -61.14%647M |
Net common stock issuance | ---330M | -99.36%-1.25B | -2,983.33%-370M | -9.84%-402M | -409.68%-474M | --0 | 56.63%-625M | 14.29%-12M | 6.63%-366M | 81.73%-93M |
Cash dividends paid | 2.78%-245M | -2.04%-1B | 1.59%-247M | -0.40%-249M | -5.00%-252M | -4.56%-252M | -6.99%-980M | -3.72%-251M | -1.64%-248M | -0.42%-240M |
Net other financing activities | 78.00%-11M | -3,666.67%-107M | -32.08%108M | -17.95%-92M | -19.67%-73M | -194.12%-50M | 175.00%3M | 59.00%159M | -269.57%-78M | 47.41%-61M |
Cash from discontinued financing activities | 0 | -14.78%-132M | -8M | 4.96%-115M | ||||||
Financing cash flow | -83.63%201M | 4.32%-2.08B | -65.38%-1.76B | 27.24%-999M | -317.79%-551M | 13,544.44%1.23B | -321.32%-2.17B | -95.05%-1.06B | -230.84%-1.37B | -68.41%253M |
Net cash flow | ||||||||||
Beginning cash position | -16.36%767M | -55.57%917M | -18.45%862M | -57.32%843M | 19.22%1.8B | -55.61%917M | 54.14%2.06B | -29.81%1.06B | 10.52%1.98B | 25.02%1.51B |
Current changes in cash | -63.09%337M | 81.70%-209M | 47.90%-149M | 90.63%-77M | -302.71%-896M | 291.81%913M | -246.79%-1.14B | -153.96%-286M | -346.74%-822M | -28.59%442M |
Effect of exchange rate changes | 156.67%154M | 1,280.00%59M | -51.61%30M | 113.33%10M | -286.36%-41M | 528.57%60M | 90.57%-5M | 1,650.00%62M | 21.05%-75M | 204.76%22M |
End cash Position | -31.24%1.24B | -26.81%606M | -26.81%606M | -18.45%862M | -57.32%843M | 19.22%1.8B | -59.19%828M | -59.19%828M | -29.81%1.06B | 10.52%1.98B |
Free cash flow | 139.94%131M | -9.63%1.6B | 3.51%1.36B | 31.34%922M | -279.27%-346M | 23.72%-328M | 18.10%1.78B | 16.34%1.31B | 121.45%702M | 200.00%193M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |